Key facts
- 2EyesVision’s last known valuation is $17.1M (Oct 2025).
- It has raised $11.4M; the latest was Equity Crowdfunding ($900K) in Oct 2025.
- Notable investors include INNVIERTE SICC, NextCorps Luminate, Bullnet Capital, EIT Health, Jan Bonel — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for 2EyesVision
- ·The full record, as it builds
Funding rounds
No funding rounds for 2EyesVision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 2EyesVision
Developer of ophthalmic technologies designed to improve the clinical ophthalmology practice and make patients' lives easy. The company commercializes a visual simulator of presbyopic corrections for patients seeking refractive or cataract surgery to experience the real world before undergoing surgery, enabling opticians to recommend a noninvasive, personalized assessment before treatment.
- Sector
- Healthcare
- HQ
- Madrid, Spain
- Founded
- 2015
- Employees
- 14
- Website
- 2eyesvision.com/
- Ownership
- Privately Held (backing)
2EyesVision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 2EyesVision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 2EyesVision in its N-PORT filings yet. We sweep new filings monthly.